Skip to Content
Authors Truong M, Yang B, Wagner J, Desotelle J, Jarrard DF
Author Profile(s)
Journal Epigenomics Volume: 5 Issue: 1 Pages: 65-71
Publish Date 2013 Feb
PubMed ID 23414321
PMC ID 3731941
Abstract

In vertebrates, DNA methylation occurs primarily at CG dinucleotides but recently, non-CG methylation has been found at appreciable levels in embryonic stem cells.To assess non-CG methylation in cancer, we compared the extent of non-CG methylation at several biologically important CG islands in prostate cancer and normal cell lines. An assessment of the promoter CG islands EVX1 and FILIP1L demonstrates a fourfold higher rate of non-CG methylation at EVX1 compared with FILIP1L across all cell lines. These loci are densely methylated at CG sites in cancer.No significant difference in non-CG methylation was demonstrated between cancer and normal. Treatment of cancer cell lines with 5-azacytidine significantly reduced methylation within EVX1 at CG and CC sites, preferentially.Non-CG methylation does not correlate with CG methylation at hypermethylated promoter regions in cancer. Furthermore, global inhibition of DNA methyltransferases does not affect all methylated cytosines uniformly.

Full Text Full text available on PubMed Central

webmaster@surgery.wisc.edu Copyright © 2017 The Board of Regents of the University of Wisconsin System